Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics

β-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease with a lumenal active site that sheds the ectodomains of membrane proteins through juxtamembrane proteolysis. BACE1 has been studied principally for its role in Alzheimer's disease as the β-secretase responsible for generating the amyloid-β protein. Emerging evidence from mouse models has identified the importance of BACE1 in myelination and cognitive performance. However, the substrates that BACE1 processes to regulate these functions are unknown, and to date only a few β-secretase substrates have been identified through candidate-based studies. Using an unbiased approach to substrate identification, we performed quantitative proteomic analysis of two human epithelial cell lines stably expressing BACE1 and identified 68 putative β-secretase substrates, a number of which we validated in a cell culture system. The vast majority were of type I transmembrane topology, although one was type II and three were GPI-linked proteins. Intriguingly, a preponderance of these proteins are involved in contact-dependent intercellular communication or serve as receptors and have recognized roles in the nervous system and other organs. No consistent sequence motif predicting BACE1 cleavage was identified in substrates versus non-substrates. These findings expand our understanding of the proteins and cellular processes that BACE1 may regulate, and suggest possible mechanisms of toxicity arising from chronic BACE1 inhibition.

[1]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Storrie,et al.  Both Post‐Golgi and Intra‐Golgi Cycling Affect the Distribution of the Golgi Phosphoprotein GPP130 , 2007, Traffic.

[3]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. , 2001, Nature neuroscience.

[4]  R. Iozzo,et al.  A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity , 2007, Oncogene.

[5]  P. Wong,et al.  Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.

[6]  M. Ohno,et al.  BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.

[7]  R. Klein,et al.  Bidirectional Eph-ephrin signaling during axon guidance. , 2007, Trends in cell biology.

[8]  S. Zaina,et al.  The Soluble Type 2 Insulin-like Growth Factor (IGF-II) Receptor Reduces Organ Size by IGF-II-mediated and IGF-II-independent Mechanisms* , 1998, The Journal of Biological Chemistry.

[9]  Stephen Abela,et al.  Dementia in Malta: Experiences of dementia patients and their caregivers , 2009, Alzheimer's & Dementia.

[10]  D. Price,et al.  Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice , 2008, Proceedings of the National Academy of Sciences.

[11]  Shinobu Inagaki,et al.  Requirement of the transmembrane semaphorin Sema4C for myogenic differentiation , 2005, FEBS letters.

[12]  Alzheimer’s Association,et al.  2009 Alzheimer's disease facts and figures , 2009, Alzheimer's & Dementia.

[13]  P. Jeffrey,et al.  Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. , 2007, Journal of neurochemistry.

[14]  D. Selkoe,et al.  Generation of amyloid β protein from its precursor is sequence specific , 1995, Neuron.

[15]  R. Doms,et al.  Maturation and Endosomal Targeting of β-Site Amyloid Precursor Protein-cleaving Enzyme , 2000, The Journal of Biological Chemistry.

[16]  B. Hyman,et al.  The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate* , 2005, Journal of Biological Chemistry.

[17]  V. Lee,et al.  BACE1 regulates voltage-gated sodium channels and neuronal activity , 2007, Nature Cell Biology.

[18]  S. Kitazume,et al.  Characterization of α2,6-Sialyltransferase Cleavage by Alzheimer's β-Secretase (BACE1)* , 2003, The Journal of Biological Chemistry.

[19]  J G Flanagan,et al.  Regulated cleavage of a contact-mediated axon repellent. , 2000, Science.

[20]  Xiuli Wu,et al.  The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.

[21]  D. Selkoe,et al.  gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. , 2003, Biochemistry.

[22]  M. Citron β‐secretase as a target for the treatment of Alzheimer's disease , 2002 .

[23]  T. Südhof,et al.  Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. , 2004, The Journal of biological chemistry.

[24]  Roland L. Dunbrack,et al.  Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase. , 2000, Journal of molecular biology.

[25]  Philippe Soriano,et al.  Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. , 1999, Genes & development.

[26]  M. Wolfe Inhibition and modulation of γ-secretase for Alzheimer’s disease , 2008, Neurotherapeutics.

[27]  Ray-Jade Chen,et al.  IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells. , 2008, Journal of molecular endocrinology.

[28]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[29]  M. Citron Beta-secretase as a target for the treatment of Alzheimer's disease. , 2002, Journal of neuroscience research.

[30]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[31]  N. Hooper,et al.  The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. , 2004, European journal of biochemistry.

[32]  P. Jeffrey,et al.  Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .

[33]  T. Furuyama,et al.  Sema4C, a Transmembrane Semaphorin, Interacts with a Post-synaptic Density Protein, PSD-95* , 2001, The Journal of Biological Chemistry.

[34]  R. Doms,et al.  Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. , 2000, The Journal of biological chemistry.

[35]  R. Henriksson,et al.  LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? , 2007, European journal of cancer.

[36]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[37]  E. Birney,et al.  The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.

[38]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[39]  S. Kitazume,et al.  Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). , 2003, The Journal of biological chemistry.

[40]  B. de Strooper,et al.  Regulated Intramembrane Proteolysis of the Interleukin-1 Receptor II by α-, β-, and γ-Secretase* , 2007, Journal of Biological Chemistry.

[41]  Charles Darwin,et al.  Experiments , 1800, The Medical and physical journal.

[42]  T. Südhof,et al.  Cleavage of Amyloid-β Precursor Protein and Amyloid-β Precursor-like Protein by BACE 1* , 2004, Journal of Biological Chemistry.

[43]  J. D. Wit,et al.  Role of semaphorins in the adult nervous system , 2003, Progress in Neurobiology.

[44]  D. Selkoe,et al.  Selective ectodomain phosphorylation and regulated cleavage of beta‐amyloid precursor protein. , 1994, The EMBO journal.

[45]  E. Hébert Mannose-6-phosphate/Insulin-like Growth Factor II Receptor Expression and Tumor Development , 2006, Bioscience reports.

[46]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[47]  D. Selkoe,et al.  Ectodomain Phosphorylation of β-Amyloid Precursor Protein at Two Distinct Cellular Locations* , 1997, The Journal of Biological Chemistry.

[48]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[49]  Joshua E. Elias,et al.  Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements , 2008, PLoS biology.

[50]  D. Selkoe,et al.  Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor* , 2005, Journal of Biological Chemistry.

[51]  D. Schlatter,et al.  Substrate and Inhibitor Profile of BACE (β-Secretase) and Comparison with Other Mammalian Aspartic Proteases* , 2002, The Journal of Biological Chemistry.

[52]  H. M. El-Shewy,et al.  The Insulin-like Growth Factor Type 1 and Insulin-like Growth Factor Type 2/Mannose-6-phosphate Receptors Independently Regulate ERK1/2 Activity in HEK293 Cells* , 2007, Journal of Biological Chemistry.

[53]  R. Vassar,et al.  Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .

[54]  Steven P Gygi,et al.  Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. , 2006, Journal of proteome research.

[55]  S. Kar,et al.  The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system , 2004, Brain Research Reviews.

[56]  P. Wong,et al.  BACE1 Knock-Outs Display Deficits in Activity-Dependent Potentiation of Synaptic Transmission at Mossy Fiber to CA3 Synapses in the Hippocampus , 2008, The Journal of Neuroscience.

[57]  H. Lipp,et al.  Mice with Combined Gene Knock-Outs Reveal Essential and Partially Redundant Functions of Amyloid Precursor Protein Family Members , 2000, The Journal of Neuroscience.

[58]  D. Selkoe,et al.  Generation of amyloid beta protein from its precursor is sequence specific. , 1995, Neuron.

[59]  A. Linstedt,et al.  A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. , 2004, Molecular biology of the cell.

[60]  B. de Strooper,et al.  The Cell Adhesion Protein P-selectin Glycoprotein Ligand-1 Is a Substrate for the Aspartyl Protease BACE1* , 2003, Journal of Biological Chemistry.

[61]  D. Selkoe,et al.  Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease , 2007, PLoS medicine.

[62]  D. Riddell,et al.  Characterization of the Ectodomain Shedding of the β-Site Amyloid Precursor Protein-cleaving Enzyme 1 (BACE1)* , 2003, Journal of Biological Chemistry.

[63]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[64]  Steven P Gygi,et al.  The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. , 2008, Journal of proteome research.

[65]  Jeffrey A. Golden,et al.  Semaphorin III is needed for normal patterning and growth of nerves, bones and heart , 1996, Nature.

[66]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.